Lucy Yan

发表

Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis

H. Zhang, S. Shahinfar, I. Salusky, 2018, Pediatric nephrology (Berlin, West).

An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis

S. Shahinfar, I. Salusky, Edward Lee, 2018, Pediatric Nephrology.

Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors

E. Heath, P. LoRusso, Yu‐Nien Sun, 2008, Investigational New Drugs.

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

A. Coxon, D. Branstetter, T. Burgess, 2010, Clinical Cancer Research.

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

T. Vu, Peiming Ma, A. van Hecken, 2017, Pharmaceutical Research.

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

T. Vu, Peiming Ma, A. van Hecken, 2017, Pharmaceutical Research.

Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis

J. Walle, I. Salusky, M. Kroenke, 2020, Pediatric Nephrology.

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects

C. Banfield, F. Malik, M. L. Monsalvo, 2015, International journal of clinical pharmacology and therapeutics.

Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors

C. Sweeney, M. Gordon, S. Eckhardt, 2007 .

Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With Migraine

Edgar Bautista, T. Vu, A. van Hecken, 2018, Clinical pharmacology and therapeutics.

Characterizing the Relationship Between AMG 334 Concentration and Capsaicin-Induced Increase in Dermal Blood Flow in Healthy Subjects and Migraine Patients Using Pharmacokinetic-Pharmacodynamic Modeling

T. Vu, Peiming Ma, J. Hoon, 2015 .

Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis

H. Zhang, S. Shahinfar, I. Salusky, 2018, Pediatric Nephrology.